| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3265008 | Digestive and Liver Disease | 2008 | 4 Pages |
Abstract
The pro-inflammatory cytokine tumor necrosis factor-α (TNF-α) plays a central role in mucosal inflammation and is a key mediator in the inflammatory cascade in both Crohn's disease (CD) and ulcerative colitis (UC). Infliximab, a monoclonal antibody against TNF-α has been proved highly effective in the clinical management of both forms of IBD. Aim of this paper is to review the mechanisms of action of infliximab in IBD.
Related Topics
Health Sciences
Medicine and Dentistry
Endocrinology, Diabetes and Metabolism
